This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
We are a multinational pharmaceutical company integrating innovative research, drug development, state-of-the-art manufacturing and sales & marketing to improve people’s lives around the world.
Zennova Pharmaceuticals Group is an international pharmaceutical company registered in Cayman, driven by innovative research and development. We have excellent development technology and world-class quality products. We provide world-class medicines of superior value to our patients.
Our strategy focuses on global research and development manufacturing in China, and we aim to serve markets around the world. We are focusing on four major therapeutic areas: ophthalmology, virology, cardiovascular, and oncology.
Explore Our Products
Make every effort to build an international full dosage form preparation center, with product sales targeting the Chinese, American, and global markets.
Perfectly solve the worldwide problem of replacing in vivo clinical endpoint with in vitro consistency evaluation, and successfully develop a blockbuster product for the treatment of Dry Eye Syndrome.
Intensive cultivation and meticulous cultivation have achieved significant original technological achievements, and the world has an exclusive platform for new drug development patent technology.
Currently, we have R&D and production facilities in New York, New Jersey, and Chengdu, China. Our state-of-the-art pharmaceutical manufacturing facility located in Chengdu Tianfu International Biotown is designed to qualify US FDA, EU EMA, and China cGMP standards.
State-of-the-art manufacturing facility compliant with FDA, EMA, and cGMP standards.
Innovative research and early-stage drug development center.
Advanced formulation and preclinical testing laboratories.
Focused on ophthalmology, oncology, virology, and cardiovascular diseases, our portfolio includes FDA-approved drugs and innovative therapies developed using proprietary platforms.
Innovative leukemia drug based on BioCarier® single-nanodrug delivery platform.
Antitumor
Breakthrough therapy for Dry Eye Syndrome using advanced in vitro evaluation models.
OphthalmicNext-generation antiviral agent targeting RNA viruses with high specificity.
AntiviralCardiovascular therapeutic for hypertension and heart failure management.
CardiovascularTargeted oncology therapy with enhanced tumor penetration and reduced side effects.
AntitumorSterile eye drops for inflammatory and degenerative ocular conditions.
OphthalmicMolecular glue drug developed in collaboration with Rapafusyn using RapaGlue™.
InnovationMultiple products approved for sale in the U.S., EU, and China markets.
FDA-ApprovedOur proprietary platforms drive breakthroughs in drug delivery, formulation, and clinical evaluation.
A proprietary single-nanodrug delivery system enabling targeted delivery, improved bioavailability, and reduced toxicity. This platform has enabled breakthrough clinical results in oncology and inflammatory diseases.
Advanced formulation platform that significantly enhances drug solubility and stability, particularly for poorly water-soluble compounds. Enables development of novel dosage forms with consistent in vitro performance.
Stay updated with Zennova's milestones, collaborations, and regulatory achievements.
To advance non-degrading molecular glue drug development. BioCarier® Technology Platform to accelerate RapaGlue™ drug development.
Read More →Chengdu Manufacturing Facility successfully completes FDA cGMP inspection.
Read More →Using BioCarier® Technology Platform. Zenno-10 shows significant advancement in leukemia treatment.
Read More →March 7-8, 2025 – Zennova successfully passed its on-site GMP quality inspection for the Pharmaceutical Production License.
Read More →For business inquiries, partnerships, or more information about our products and technologies, please visit our official website.
Visit Official WebsiteNotice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact [email protected] via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系[email protected] 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact [email protected]
如果您是其他域名合作 也请联系[email protected]